Sophia Debt To Equity from 2010 to 2025

SOPH Stock  USD 4.60  0.27  5.54%   
Sophia Genetics' Debt To Equity is increasing with very volatile movements from year to year. Debt To Equity is predicted to flatten to 0.19. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.31122396
Current Value
0.19
Quarterly Volatility
0.08120399
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sophia Genetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sophia Genetics' main balance sheet or income statement drivers, such as Tax Provision of 1.3 M, Net Interest Income of 1.5 M or Interest Income of 1.7 M, as well as many indicators such as Price To Sales Ratio of 2.96, Dividend Yield of 0.0 or PTB Ratio of 2.0. Sophia financial statements analysis is a perfect complement when working with Sophia Genetics Valuation or Volatility modules.
  
Build AI portfolio with Sophia Stock
Check out the analysis of Sophia Genetics Correlation against competitors.

Currently Active Assets on Macroaxis

When determining whether Sophia Genetics SA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sophia Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sophia Genetics Sa Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sophia Genetics Sa Stock:
Check out the analysis of Sophia Genetics Correlation against competitors.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sophia Genetics. If investors know Sophia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sophia Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
1.092
Quarterly Revenue Growth
0.228
Return On Assets
(0.26)
Return On Equity
(0.86)
The market value of Sophia Genetics SA is measured differently than its book value, which is the value of Sophia that is recorded on the company's balance sheet. Investors also form their own opinion of Sophia Genetics' value that differs from its market value or its book value, called intrinsic value, which is Sophia Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sophia Genetics' market value can be influenced by many factors that don't directly affect Sophia Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sophia Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sophia Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sophia Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.